Faze Three Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 1:26 pm

Quick Insight

Faze Three Ltd, operating in the textiles-spinning-cotton blended industry, currently trades at a price of 438, with a market capitalization of 1,066 Cr. The company's P/E ratio stands at 23.1, indicating a moderate valuation level, while ROE and ROCE are at 10.2% and 11.6%, respectively, reflecting decent profitability and capital efficiency. With an OPM of 12% and a net profit of 41 Cr, Faze Three Ltd appears to have stable operational performance. However, the absence of significant promoter or institutional ownership raises governance concerns. The company's healthy reserves of 396 Cr and manageable borrowings of ₹192 Cr suggest a sound financial position. The current P/BV ratio of 2.00x and ICR of 6.34x indicate reasonable valuation and debt coverage levels, respectively. Overall, Faze Three Ltd presents a mixed picture, with solid financial fundamentals but potential corporate governance risks that investors should carefully consider.

Competitors of Faze Three Ltd

All Competitor Stocks of Faze Three Ltd

Quarterly Result

Last Updated: August 19, 2025, 3:45 pm

Below is a detailed analysis of the quarterly data for Faze Three Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 212.00 Cr.. The value appears strong and on an upward trend. It has increased from 211.00 Cr. (Mar 2025) to 212.00 Cr., marking an increase of 1.00 Cr..
• For Expenses, as of Jun 2025, the value is 187.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 186.00 Cr. (Mar 2025) to 187.00 Cr., marking an increase of 1.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
• For OPM %, as of Jun 2025, the value is 12.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 4.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 18.00% (Mar 2025) to 25.00%, marking an increase of 7.00%.
• For Net Profit, as of Jun 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 4.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 5.25. The value appears to be declining and may need further review. It has decreased from 7.17 (Mar 2025) to 5.25, marking a decrease of 1.92.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:30 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:19 pm

Below is a detailed analysis of the balance sheet data for Faze Three Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
• For Reserves, as of Mar 2025, the value is 396.00 Cr.. The value appears strong and on an upward trend. It has increased from 356.00 Cr. (Mar 2024) to 396.00 Cr., marking an increase of 40.00 Cr..
• For Borrowings, as of Mar 2025, the value is 192.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 170.00 Cr. (Mar 2024) to 192.00 Cr., marking an increase of 22.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Mar 2024) to 74.00 Cr., marking an increase of 31.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 686.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 593.00 Cr. (Mar 2024) to 686.00 Cr., marking an increase of 93.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 306.00 Cr.. The value appears strong and on an upward trend. It has increased from 252.00 Cr. (Mar 2024) to 306.00 Cr., marking an increase of 54.00 Cr..
• For CWIP, as of Mar 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2024) to 9.00 Cr., marking an increase of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2024) to 11.00 Cr., marking a decrease of 3.00 Cr..
• For Other Assets, as of Mar 2025, the value is 362.00 Cr.. The value appears strong and on an upward trend. It has increased from 321.00 Cr. (Mar 2024) to 362.00 Cr., marking an increase of 41.00 Cr..
• For Total Assets, as of Mar 2025, the value is 686.00 Cr.. The value appears strong and on an upward trend. It has increased from 593.00 Cr. (Mar 2024) to 686.00 Cr., marking an increase of 93.00 Cr..

Notably, the Reserves (396.00 Cr.) exceed the Borrowings (192.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Faze Three Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 16.72. This value is within the healthy range. It has decreased from 19.16 (Mar 24) to 16.72, marking a decrease of 2.44.
• For Diluted EPS (Rs.), as of Mar 25, the value is 16.72. This value is within the healthy range. It has decreased from 19.16 (Mar 24) to 16.72, marking a decrease of 2.44.
• For Cash EPS (Rs.), as of Mar 25, the value is 27.01. This value is within the healthy range. It has decreased from 27.63 (Mar 24) to 27.01, marking a decrease of 0.62.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 172.71. It has increased from 133.46 (Mar 24) to 172.71, marking an increase of 39.25.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 172.71. It has increased from 156.52 (Mar 24) to 172.71, marking an increase of 16.19.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 283.69. It has increased from 232.12 (Mar 24) to 283.69, marking an increase of 51.57.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 37.92. This value is within the healthy range. It has decreased from 38.77 (Mar 24) to 37.92, marking a decrease of 0.85.
• For PBIT / Share (Rs.), as of Mar 25, the value is 27.63. This value is within the healthy range. It has decreased from 30.30 (Mar 24) to 27.63, marking a decrease of 2.67.
• For PBT / Share (Rs.), as of Mar 25, the value is 21.65. This value is within the healthy range. It has decreased from 25.68 (Mar 24) to 21.65, marking a decrease of 4.03.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 16.72. This value is within the healthy range. It has decreased from 19.16 (Mar 24) to 16.72, marking a decrease of 2.44.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.72. This value is within the healthy range. It has decreased from 19.16 (Mar 24) to 16.72, marking a decrease of 2.44.
• For PBDIT Margin (%), as of Mar 25, the value is 13.36. This value is within the healthy range. It has decreased from 16.70 (Mar 24) to 13.36, marking a decrease of 3.34.
• For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 13.05 (Mar 24) to 9.73, marking a decrease of 3.32.
• For PBT Margin (%), as of Mar 25, the value is 7.63. This value is below the healthy minimum of 10. It has decreased from 11.06 (Mar 24) to 7.63, marking a decrease of 3.43.
• For Net Profit Margin (%), as of Mar 25, the value is 5.89. This value is within the healthy range. It has decreased from 8.25 (Mar 24) to 5.89, marking a decrease of 2.36.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.89. This value is below the healthy minimum of 8. It has decreased from 8.25 (Mar 24) to 5.89, marking a decrease of 2.36.
• For Return on Networth / Equity (%), as of Mar 25, the value is 9.68. This value is below the healthy minimum of 15. It has decreased from 14.35 (Mar 24) to 9.68, marking a decrease of 4.67.
• For Return on Capital Employeed (%), as of Mar 25, the value is 15.39. This value is within the healthy range. It has decreased from 18.50 (Mar 24) to 15.39, marking a decrease of 3.11.
• For Return On Assets (%), as of Mar 25, the value is 5.92. This value is within the healthy range. It has decreased from 7.85 (Mar 24) to 5.92, marking a decrease of 1.93.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.48 (Mar 24) to 0.42, marking a decrease of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.08. It has increased from 0.99 (Mar 24) to 1.08, marking an increase of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 1.42. This value is below the healthy minimum of 1.5. It has decreased from 1.65 (Mar 24) to 1.42, marking a decrease of 0.23.
• For Quick Ratio (X), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.63, marking a decrease of 0.33.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 4. It has decreased from 2.69 (Mar 24) to 2.28, marking a decrease of 0.41.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.34. This value is within the healthy range. It has decreased from 8.38 (Mar 24) to 6.34, marking a decrease of 2.04.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.79. This value is within the healthy range. It has decreased from 5.14 (Mar 24) to 3.79, marking a decrease of 1.35.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,013.17. It has increased from 955.25 (Mar 24) to 1,013.17, marking an increase of 57.92.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.47. This value is within the healthy range. It has decreased from 1.69 (Mar 24) to 1.47, marking a decrease of 0.22.
• For EV / EBITDA (X), as of Mar 25, the value is 10.99. This value is within the healthy range. It has increased from 10.13 (Mar 24) to 10.99, marking an increase of 0.86.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.22. This value is within the healthy range. It has decreased from 1.54 (Mar 24) to 1.22, marking a decrease of 0.32.
• For Price / BV (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.67 (Mar 24) to 2.00, marking a decrease of 0.67.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.22. This value is within the healthy range. It has decreased from 1.54 (Mar 24) to 1.22, marking a decrease of 0.32.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness